Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib, Trametinib in patients with Melanoma.
The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.